RheumNow
Rheumnow.com serves as a dedicated news platform focused on Rheumatology. Crafted by specialists in the field, it caters to Rheumatologists and professionals in related areas. The site offers daily updates, and you can also receive the latest news directly in your inbox by subscribing to our newsletter.
Outlet metrics
Global
#826406
India
#137479
Health/Health
#1328
Articles
-
5 days ago |
rheumnow.com | Jack Cush
An overview of denosumab use in osteoporosis (OP) by Bauer and Ensrud was published in JAMA. Denosumab plays an important role in OP guidelines, often secondary to antiresorptive agents such as bisphosphonates (usual first-line therapy). Yet, denosumab is recommended as it is more convenient, has fewer gastrointestinal adverse effects, and its use is increasing while bisphosphonate use remains constant. 3-year persistence with denosumab and bisphosphonates are similar (approximately 50%).
-
1 week ago |
rheumnow.com | Jack Cush
Dr. Jack Cush reviews the book/movie, "Moneyball" and a suggests moneyball strategy is needed to find next level responses for our patients.
-
1 week ago |
rheumnow.com | Jack Cush
A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care. A post hoc study included pooled data from belimumab trials (Be-SLE; BLISS-52, BLISS-76, BLISS-SC, and EMBRACE) conducted between 2007 and 2018. Adults with active SLE were treated with either BEL (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or placebo, plus standard therapy (ST).
-
1 week ago |
rheumnow.com | Jack Cush
The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. Overall, the goals of SLE management are to achieve remission or a low level disease activity, reduce morbidity and mortality, and minimize treatment-related adverse events.
-
1 week ago |
rheumnow.com | Jack Cush
A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS). Certolizumab (CZP) was shown to reduced the risk of adverse pregnancy outcomes (APOs) in high-risk patients with APS.
RheumNow journalists
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Email Patterns
Website
http://rheumnow.comTry JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →